Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments.

The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. 

Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who don't respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.


SOSV

RebelBio

Greater London Authority

Hoxton Ventures

Fly Ventures

Wavemaker 360

Octopus Ventures

Compound

Crista Galli Ventures

Pear Bio

Our Winter 2023 newsletter now out, with a focus on our clinical trial work

https://lnkd.in/ewiz_XVw

Let us know if you have questions, or want to know more about our clinical trials!

The Pear Bio team is excited to have set up our first US lab in the Boston area at ABI-LAB 2 this month! The facilities and support provided by the team are second to none 🇺🇸  🇺🇸  🇺🇸 

This lab will focus on US clinical trials & lab developed testing.

We are looking forward to this new chapter for the company!

Really delighted that we have support from a range of charities for our trials.

Pear-Tree2 in kidney cancer from Kidney Cancer UK
Pear-TNBC in Triple Negative Breast Cancer from Breast Cancer Now

and both are open across a range of hospitals

https://lnkd.in/d5iYhvgV
https://lnkd.in/dYrU_EiZ

To read more about our trials, see here: https://lnkd.in/dvJkA5CN

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	80931f78
crunchbase profile	general
li profile	general	Feb 6, 2024 10:23 AM	dc9c7cde
translate crunchbase fundingrounds	general
peers	general	Feb 6, 2024 10:23 AM	963c6158
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PEARBIO

Pear Bio